Travere Therapeutics, Inc. (NASDAQ: TVTX), a biopharmaceutical company headquartered in San Diego, California, is focused on developing therapies for rare kidney and metabolic diseases. With a market capitalization of $2.75 billion, Travere has positioned itself as a notable player in the biotechnology sector. Despite operating in a challenging industry landscape, the company has captured investor attention, particularly with its promising 39% potential upside based on analyst target prices.

**Price and Valuation Metrics**

Currently trading at $30.73 per share, Travere’s stock has experienced a price change of just 0.34 (0.01%), reflecting a relatively stable performance amidst market fluctuations. The stock’s 52-week range of…